A decade after cultivated meat first captured investor interest with the promise of producing animal protein without raising livestock, the industry is repositioning its expectations and market strategy. Rather than aiming to replicate premium cuts like steaks at scale, many startups are focusing on niche markets where the technology can currently offer clear advantages or justify higher prices.

The production process begins with sampling animal or plant cells, which are then grown in nutrient-rich bioreactors. In theory, this approach could decouple food production from traditional farming and fishing methods. However, challenges related to high costs, regulatory hurdles, scaling difficulties, and consumer acceptance have slowed progress, especially as investment in the sector has decreased sharply since a peak in 2021.

According to data from the Good Food Institute, funding for alternative protein companies fell from over $5 billion in 2021 to $881 million last year, with cultivated meat and seafood firms accounting for only $74 million. Some investors and entrepreneurs now argue that early startups underestimated the industrial complexity and financial discipline required to succeed.

Jim Mellon, a British investor active in cultivated meat and fermentation ventures, noted that some companies mistakenly treated their operations like technology startups, expecting high margins and employee perks common in Silicon Valley. Instead, he emphasized that cultivated food manufacturing is an industrial process with tighter margins that demands scalable production facilities and regulatory approvals.

Several startups are seeking to enter markets adjacent to human consumption. Meatly, backed by Mellon's Agronomics, has launched cultivated chicken-based dog treats in partnership with a plant-based pet food brand and a retail chain in the UK. Meatly’s CEO Owen Ensor highlighted pet food as a potentially more accessible market, given its sizable global value and reliance on volatile meat byproduct supplies. However, Ensor acknowledged that scaling manufacturing remains challenging, citing the sensitivity of animal cells to bioreactor conditions and contamination risks.

Meanwhile, Hoxton Farms, a London-based company focused on cultivated pork fat, is targeting processed meat manufacturers. Co-founder Max Jamilly argued that fat plays a crucial but often overlooked role in taste and texture, and replacing conventionally sourced fat with cultivated alternatives could improve product consistency and supply chain stability. Hoxton has raised approximately $35 million and is pursuing regulatory approval beginning in Asia, with dossiers submitted in Singapore and a partnership in Japan.

Seafood represents another growth area. Wildtype, a U.S. startup producing cell-based salmon, has begun commercial shipments following regulatory discussions with the U.S. Food and Drug Administration. Co-founder Justin Kolbeck emphasized the appeal of salmon free from pollutants and antibiotics, while co-founder Aryé Elfenbein noted that presenting cultivated salmon in recognizable, high-quality sushi form helps engage consumers.

Efforts extend beyond meat and seafood. Celleste Bio, an Israeli company supported by Mondelez, is developing chocolate using cell-cultured cocoa butter. The company says its product has the same chemical composition as traditional cocoa butter and can serve as a direct replacement in manufacturing, providing a more reliable supply amid cocoa price fluctuations. Celleste aims for regulatory approval in the U.S. and Israel by late 2025 and targets large-scale production by 2035.

Despite these advances, significant obstacles remain. Public wariness of "lab-grown" foods persists, though many in the industry prefer the term "cultivated." Regulatory frameworks are still evolving, with some U.S. states imposing restrictions on cultivated meat. Most importantly, no company has yet demonstrated the ability to produce cultivated food at prices competitive with conventional options on a mass scale.

Mellon believes the sector holds promise to alleviate food insecurity, reduce environmental impacts, and stabilize supply chains—if it can operate as a viable business rather than relying solely on ethical arguments. “If we don’t have the capitalist motive to make this work, then it’s not going to work,” he said, underscoring the industry's need for commercial sustainability alongside innovation.